homepagecommon questionsarchiveinfocontacts
forumbulletinfieldsreads

Clinical Developments for AXN-2510/IMM2510 in NSCLC Show Promise

March 4, 2025 - 12:22

Clinical Developments for AXN-2510/IMM2510 in NSCLC Show Promise

Recent updates have highlighted significant advancements in the clinical development of AXN-2510/IMM2510, particularly in the treatment of relapsed and refractory non-small cell lung cancer (NSCLC) in China. ImmuneOnco is expected to release clinical data related to the monotherapy of AXN-2510/IMM2510 in the first half of 2025. This data is eagerly anticipated as it could provide valuable insights into the efficacy of the treatment.

Furthermore, the enrollment of patients with first-line NSCLC for a trial combining AXN-2510/IMM2510 with chemotherapy is projected to begin in the second quarter of 2025. Initial clinical results from this trial are expected to be available in the latter half of 2025, potentially paving the way for new treatment protocols.

In addition, plans are underway to initiate a U.S. clinical study of AXN-2510/IMM2510 in conjunction with chemotherapy for first-line NSCLC patients, with expectations for this to commence before the end of the year. These developments reflect a growing commitment to advancing therapies for NSCLC and improving patient outcomes.


MORE NEWS

Nasdaq Starts Charging for Financial Crime AI Agents as 850 Customers Sign On

November 22, 2026 - 00:48

Nasdaq Starts Charging for Financial Crime AI Agents as 850 Customers Sign On

Nasdaq is taking a significant step by implementing fees for its artificial intelligence agents designed to combat financial crime. This move comes as the company seeks to expand its offerings in...

Key Insights for Long-Term Investors in Globant

November 21, 2026 - 04:20

Key Insights for Long-Term Investors in Globant

Globant`s recent shift to outcome-based pricing has shown promising results, particularly in its impact on gross margins. This new pricing strategy has already lifted gross margins by approximately...

Docusign to Release Third Quarter Financial Results on December 3, 2026

November 20, 2026 - 02:05

Docusign to Release Third Quarter Financial Results on December 3, 2026

Docusign has announced that it will share its financial results for the third quarter of fiscal 2027 after the U.S. markets close on Thursday, December 3, 2026. Following the release, the company...

Royal Gold Expands Board with Mining Veteran Harry Kenyon-Slaney

November 19, 2026 - 01:35

Royal Gold Expands Board with Mining Veteran Harry Kenyon-Slaney

DENVER, November 18, 2026--Royal Gold has taken a significant step in enhancing its leadership by appointing Harry Kenyon-Slaney to its Board of Directors. Kenyon-Slaney brings a wealth of...

read all news
homepagecommon questionsarchiveinfocontacts

Copyright © 2026 Taxlyf.com

Founded by: Audrey Bellamy

forumbulletinfieldsrecommendationsreads
terms of useyour datacookie info